JERUSALEM, March 27, 2014 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM:ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the first patient has been enrolled in its U.S. Phase 2a trial for its orally ingestible insulin capsule, ORMD-0801, in the treatment of type 1 diabetes (T1DM).

“We are pleased to be initiating this U.S. clinical trial with ORMD-0801 in patients with type 1 diabetes following successful trials outside of the US,” said Nadav Kidron, CEO of Oramed Pharmaceuticals. “This initiation is in parallel to the company gearing up for its multi-center Phase IIb study for the treatment of type 2 diabetics.”

This Phase 2a clinical trial is a prospective, randomized, double-blind, placebo-controlled study designed to enroll up to 24 patients with type 1 diabetes in-clinic for 10 days. Patients will be randomized in a 2:1 ratio to receive either ORMD-0801 or placebo. The primary endpoint of the trial is to evaluate the change from baseline in exogenous insulin requirements (basal, bolus, and total) in patients treated with ORMD-0801, compared to the change from baseline for patients treated with placebo. Secondary endpoints include evaluating the change from baseline in mean nighttime, daytime, and fasting glucose levels in type 1 diabetes patients treated with ORMD-0801, compared to the change from baseline for patients treated with placebo. For more details on the trial, please visit http://www.clinicaltrials.gov.

About ORMD-0801 Oral Insulin and T1DM

Oramed proposes to introduce ORMD-0801 to reduce the mealtime insulin doses, introducing a treatment regimen which would allow for fewer daily injections. Moreover, oral administration offers the benefit of reduced systemic exposure and may enable tighter regulation of blood sugar levels by directly affecting glucose control in the liver.

WILMINGTON, Mass., March 25, 2014 /PRNewswire/ — Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that its QS-B220 desktop explosives trace detector (ETD) has received regulatory approval from the German Federal Ministry of the Interior  for aviation security applications at German airports. The QS-B220 fulfills specifications set by the German Federal Police. With the German Federal Ministry of the Interior approval, the QS-B220 may now be deployed at all non-passenger airport checkpoints for screening of deliveries, food service, and other airport service functions.

Testing and evaluation was conducted at the German National Test Center for the Evaluation of Explosives Detection Systems, established by the German Federal Police, in conjunction with the Fraunhofer Institute for Chemical Technology (ICT). The realistic testing environment provided by the Center is essential for security services and end users such as airport operators to obtain reliable performance data and ensure a uniform security standard throughout Europe.

“This testing was performed at the request of an airport in Germany that plans to use the QS-B220 to speed up their inspection process at apron checkpoints. Successful completion of the approval process opens up opportunities at airports through the region,” stated Implant Sciences’ Vice President of Sales and Marketing, Dr. Darryl Jones.

“This product approval, which was performed using the latest test protocols and obtained through a key testing facility, further solidifies Implant Sciences’ role as the new standard of trace detection. Our plan is to continue to expand our range of certifications, which includes the U.S., France, China, and now Germany. We believe this will allow us to increase sales volumes and revenues for our Company,” added Implant Sciences’ President and CEO, Glenn D. Bolduc.

On February 4, 2013, the EU implemented an amendment to Regulation (EU) No 185/2010, in regards to the screening of passengers and persons other than passengers by Explosives Trace Detection (ETD) equipment in combination with Handheld Metal Detection (HHMD) equipment, which stated that “trials have demonstrated the effectiveness of the combined use of ETD and HHMD.  Moreover, the use of ETD and HHMD may facilitate the screening process and be experienced to be a less intrusive means of screening than a hand search, thus constituting an improvement in the experience of persons screened.”

HAIFA, Israel, March 25, 2014 (GLOBE NEWSWIRE) — Pluristem Therapeutics, Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced its participation in the 2nd UK-Israel Regenerative Medicine Conference (BIRAX), which is being held on March 25th and 26th, 2014 in Haifa at the Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology.

Ohad Karnieli, Pluristem’s Vice President of Development & Manufacturing will be a panelist on a session focused on commercialization of regenerative medicine titled, “Road to Clinical Translation — The viewpoint from Industry,” on March 26th, at 4:20 pm.

Shani Raveh, Ph.D., Pluristem’s Scientist will present a scientific poster titled, “Prevention of GvHD by PLX-PAD Cells via intravenous (IV) or intramuscular (IM) Administration”. Preliminary results from Pluristem’s preclinical study of its Placental eXpanded cells (PLX) in the prevention of graft versus host disease (GvHD) were announced in October, 2013. Dr. Raveh will present this data. Conclusions of the preclinical study include:

a) PLX-PAD administration mitigates GvHD symptoms, suggesting that it may be an effective and novel prophylactic treatment for GvHD; and

b) The beneficial effect of PLX-PAD is achieved by both IM and IV routes of administration implying that the systemic effect can be achieved also by local administration.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an “off-the-shelf” product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

HAIFA, Israel, March 26, 2014 (GLOBE NEWSWIRE) — Pluristem Therapeutics, Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that a delegation from the UK made an official visit to Pluristem on March 25, 2014. Officials visiting Pluristem included the UK’s Minister for Universities and Science, David Willetts, whose responsibilities include overseeing the Department of Business Innovation and Skills (BIS), and Dr. Stephen Ward, Chief Operating Officer of the Cell Therapy Catapult, a non-profit organization which aims to grow the UK cell therapy industry.

British Prime Minster David Cameron recently launched a call for ground breaking collaborative research between Britain and Israel into Alzheimer’s, Type 1 Diabetes, heart disease, and Parkinson’s. British delegates including Mr. Willetts and Mr. Ward were in Israel to participate in the 2nd UK-Israel Regenerative Medicine Conference (BIRAX), which is being held on March 25th and 26th, 2014 in Haifa.

Minister David Willets stated, “In recent years, Israel has emerged as a leading player in the biomedical arena and in particular in the cell therapy space. Our objective is to deepen cooperation in scientific and clinical trials between Israel and the United Kingdom by establishing strategic partnerships with leading medical centers in the UK and Israeli companies.”

“It was an honor to host Minister Willetts, Dr. Ward, and members of their delegation here at Pluristem. We look forward to further talks regarding cooperation and collaboration with the British government and UK-based companies. As we accelerate our clinical pipeline, we are evaluating various locations for our clinical trials as well as other business partnership initiatives. We see the UK as an attractive territory that potentially enables a shorter path to market for our PLX products, particularly if the UK approves the Promising Innovation Medicine legislation that would speed up patients’ access to innovative new therapies,” commented, Pluristem CEO Zami Aberman.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an “off-the-shelf” product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team.

BOTHELL, WA–(Marketwired – Mar 21, 2014) – Borneo Resource Investments Ltd. (OTCQB: BRNE), (the “Company” or “Borneo”), today announced that it hired Terrence Kirk Filbert to serve as Managing Director – Asia. Mr. Filbert previously served as the Managing Director of Big Blue Resources (Holdings) Limited, an owner of thermal coal mining concession licenses in East and Central Kalimantan, and high grade Silica concessions in Central Kalimantan, Indonesia. Mr. Filbert has intimate knowledge of the coal and mineral businesses in Indonesia and will be instrumental in increasing Borneo’s presence in the Asian markets and increasing Borneo’s gold and coal land portfolios.

Borneo is looking to expand its land portfolio beyond its four gold properties in and around Talawaan and Ratatotok. The Company is moving forward on developing a second steady stream of revenue on its Ratatotok South property. Borneo is currently near the end of its processing cycle at Ratatotok and the ore enhanced carbon will be moved from the site to the Company’s facilities in Manado for final processing.

With the revenue generated in Ratatotok, the Company plans to repay the two remaining notes it has with Asher Enterprises, Inc. These notes are due in April and June 2014 in the amounts of $32,500 and $42,500, respectively. In February 2014, the Company repaid its first convertible note with Asher that had a principal balance of $37,500.

“Bringing aboard Terry Filbert will allow Borneo to increase its visibility in the Asian financial markets, and the coal and mineral marketplace. As Borneo grows with Terry and its current management team, we plan to generate an increasing amount of capital through our business operations and connections in the mineral markets in Asia,” commented Borneo CEO Nils Ollquist.

About Borneo Resource Investments Ltd.

Borneo Resource Investments Ltd. (OTCQB: BRNE) is a mining company that mines gold and develops producing gold mines as well as coal mining properties in the Republic of Indonesia. Borneo’s current assets include three gold properties, two of which are producing gold. Cash flow-producing investments in gold properties help fund Borneo’s operations and investments in gold, while the Company develops high value, longer-term investments in thermal “coal concessions,” which are properties that can be mined for coal. Borneo currently has one coal concession in the Borneo region of Indonesia. Indonesia was the 8th largest gold producing nation in 2012 and the world’s largest exporter of coal, with $25 billion exported in 2012.